Kirk D. Malloy Ph.D.
Dr. Kirk D. Malloy has held management and executive leadership positions in rapidly-growing life science and diagnostics companies for over 20 years. He is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics, and genomics companies. Prior to BioAdvisors, he was Senior Vice President and General Manager of Life Sciences and Applied Markets at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays, and software for the life science and diagnostics markets. In this role, he ran the company’s largest business unit with a P&L of over $1B and was responsible for the company's core platform technologies. His business unit served the life sciences and applied markets (Agrigenomics, Microbiology, Transplant Biology, Forensics, Complex Diseases, and Healthy Clinical Genomes). He joined Illumina in 2002 and previously managed a team of 450 in 50 countries as Vice President of Global Customer Solutions and Vice President of Quality, building and leading the commercial support and training organization and a professional service business generating more than $120M in annual revenues.
Prior to joining Illumina, Dr. Malloy built and managed commercial training, support, and validation services at Biosite Inc., a leading provider of rapid diagnostics products, where he helped build the point-of-care cardiovascular diagnostics test market. Before Biosite, Malloy held various management roles and helped build the North American commercial organization at QIAGEN, Inc., a provider of molecular biology reagents and for the life sciences, veterinary, diagnostics, and applied markets. Before joining industry, Dr. Malloy spent several years as an academic scientist teaching and conducting research.
Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University. He completed a certification for Corporate Directors at UCLA’s Anderson School in 2012 and currently serves as Lead Independent Director for Organovo (NYSE: ONVO), and serves as a corporate director on the boards of iGenomx, Edico Genome, and is Chairman of the Board for Agilome. Kirk is an associate of Growth Source Inc. where he provides strategic consulting and executive coaching for rapidly-growing biotech companies. He also serves on the Board of Trustees for the Pacific Ridge School, and is on the Dean’s Advisory Board for the University of Delaware. He has 12 peer-reviewed publications and book chapters, dozens of invited and contributed scientific presentations, and has been a reviewer for various scientific journals.